What We're Reading: Page 375
Industry reads hand-picked by our editors
Dec 16, 2014
-
-
Fierce Pharma
Abbott closes Veropharm deal amidst US-Russia political tension
-
-
Indian Supreme Court rejects Bayer's bid to block cheap cancer generic
-
-
Jazz pushing potential $1B rare disease drug through rolling NDA
-
Federal judge: Actavis must keep selling older version of Alzheimer's drug
-
-
Novartis psoriasis drug bests J&J's Stelara in head-to-head trial
-
Dec 15, 2014
-
Philly transit authority launches class action against Gilead over Sovaldi price
-
Compromise: Branded biologics, biosimilar firms reach hard-won agreement
-
-
Teva 2015 revenue forecast $1 billion lower than expected
-
-
Gavi pledges $300M to get Ebola vaccines to hard-hit countries
-
-
-
-
Lawmakers propose new antibiotics pathway to combat superbugs
Dec 12, 2014
-
-
FDA approves new HPV super-vaccine, Merck's Gardasil 9
-
'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden
-
-
Teva launches generic of Pfizer's arthritis med Celebrex in the US
-
-
Merck, NewLink Ebola vax trial suspended over joint pain complaints
-
ICYMI: AARP and GPhA on what to do about generic drug price hikes
-
-
Mylan to foot $20M tax penalty for top execs after inversion merger
Dec 11, 2014
-
Indian company first to the finish line with historic Humira biosimilar
-
A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents
-
-
-
Feds refuse to hear Sandoz case related to biosimilar development efforts
-
-
After failed Allergan offensive, Valeant finally taking break from M&A focus
-
HHS extends legal immunity to Ebola vaccine makers
-
-
Bluebird shares skyrocket on promising gene therapy-blood disorder data
Dec 10, 2014
-
-
Feds drop wire fraud charges against former Lilly scientists
-
CEO of growing biopharma CRO killed in Maryland small jet crash
-
-
-
Pfizer creating gene therapy platform to expand rare disease efforts
-
-
-
Microsoft co-founder Allen donates $100M to unlock mysteries of the human cell
-
France, Germany, other EU countries suspend Indian generics approvals
Dec 09, 2014
-
Merck to buy antibiotics powerhouse Cubist for $9.5 billion
-
Why CRO employee turnover is still so high
-
FDA: A defined biosimlar pathway is coming—soon
-
Merck, BMS PD-1 drugs continue to roll, show promise for Hodgkin's lymphoma
-
-
-
-
-
Some more firsts for Incyte: Jakafi approved for chronic bone marrow disease
-
Dec 08, 2014
-
-
Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory
-
-
The FDA's new effort to make it easier to create generics of risky drugs
-
-
-
Google's secretive Calico looking to hire bioinformatics pro
-
-
-
GSK reverses course, retracts plan to sell older drugs
Previous
